Prostate cancer is the leading cancer among men, with about 1 out of every 7 diagnosed during their lifetime. It is estimated that there were 21,300 new cases and 4,100 deaths in Canada in 2017. Inheritance is one of the three most common factors for the disease, in addition to age and race. Mutations in both BRCA1 and BRCA2, which are associated with hereditary breast and/or ovarian cancer in females, have also been shown to be risk factors for incidences of prostate cancer in males. BRIP1, BRCA1 interacting protein 1, has also been associated with breast/ovarian cancer. Though increasing evidence suggests that BRIP1 is a hereditary prostate cancer gene, its connection is uncertain. In this project, we will investigate the pathogenesis of hereditary BRIP1 mutations leading to prostate cancer. In addition to evaluation of PARP inhibitors on prostate cancer, we will also use a high-throughput to screen small molecule libraries and identify small molecules that modulate BRIP1’s function, aiming to identify novel chemotherapeutic agents that selectively kill BRIP1 associated tumor cells. We believe that identifying BRIP1 as a prostate cancer-predisposing gene and finding inhibitors targeting BRIP1 might be exploited to advance diagnosis, prognosis, and treatment of prostate cancer patients.